Skip to main
OPT
OPT logo

Opthea (OPT) Stock Forecast & Price Target

Opthea (OPT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Opthea Ltd is focused on advancing its novel biologic therapy, OPT-302, for eye diseases, specifically targeting key vascular growth factors, which positions it well within the medical technology and healthcare sector. The company aims to demonstrate substantial vision improvements in patients through its Phase 3 trials, with a notable previous performance indicating a +5.7 letter gain in visual acuity among a significant patient subgroup, which suggests a promising potential for commercial adoption by retinal specialists. Furthermore, the alignment of clinical efficacy with payer outlooks on vision improvement thresholds enhances the company’s likelihood of securing broad market coverage and strengthens the basis for a positive investment perspective.

Bears say

Opthea Ltd reported a significant net loss of $131.9 million, or $0.11 per share, for the first half of FY 2025, raising concerns about its financial sustainability. The company faces several risks, including the potential failure of its developmental candidate, OPT-302, to meet projected peak commercial revenue estimates, which could be impacted by market size, penetration rates, and pricing strategies. Additionally, Opthea's ability to secure necessary capital resources for ongoing operations and program development remains uncertain, further contributing to a negative outlook on its financial stability.

Opthea (OPT) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opthea and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opthea (OPT) Forecast

Analysts have given Opthea (OPT) a Buy based on their latest research and market trends.

According to 8 analysts, Opthea (OPT) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opthea (OPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.